Your browser doesn't support javascript.
loading
Biomarker analysis of the phase II JO25567 study comparing erlotinib with or without bevacizumab in first-line advanced EGFR+non-small-cell lung cancer.
Nishio, Makoto; Atagi, Shinji; Goto, Koichi; Hosomi, Yukio; Seto, Takashi; Hida, Toyoaki; Nakagawa, Kazuhiko; Yoshioka, Hiroshige; Nogami, Naoyuki; Maemondo, Makoto; Nagase, Seisuke; Okamoto, Isamu; Yamamoto, Noboru; Igawa, Yuriko; Tajima, Kosei; Fukuoka, Masahiro; Yamamoto, Nobuyuki; Nishio, Kazuto.
Afiliación
  • Nishio M; Department of Thoracic Medical Oncology, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan.
  • Atagi S; Health Management Center, Japan Community Health Care Organization, Yamato Koriyama Hospital, Nara, Japan.
  • Goto K; Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
  • Hosomi Y; Department of Thoracic Oncology and Respiratory Medicine, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan.
  • Seto T; Department of Thoracic Oncology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan.
  • Hida T; Lung Cancer Center, Central Japan International Medical Center, Gifu, Japan.
  • Nakagawa K; Department of Medical Oncology, Kindai University, Faculty of Medicine, Osaka, Japan.
  • Yoshioka H; Department of Thoracic Oncology, Kansai Medical University Hospital, Osaka, Japan.
  • Nogami N; Department of Cardiology, Pulmonology, Hypertension and Nephrology, Ehime University, Graduate School of Medicine, Ehime, Japan.
  • Maemondo M; Division of Pulmonary Medicine, Department of Internal Medicine, Iwate Medical University School of Medicine, Iwate, Japan.
  • Nagase S; Department of Thoracic Oncology, International University of Health and Welfare Mita Hospital, Tokyo, Japan.
  • Okamoto I; Department of Respiratory Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
  • Yamamoto N; Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan.
  • Igawa Y; Chugai Pharmaceutical Co., Ltd., Tokyo, Japan.
  • Tajima K; Chugai Pharmaceutical Co., Ltd., Tokyo, Japan.
  • Fukuoka M; Department of Medical Oncology, Izumi City General Hospital, Osaka, Japan.
  • Yamamoto N; Internal Medicine III, Wakayama Medical University, Wakayama, Japan.
  • Nishio K; Department of Medical Oncology, Kindai University, Faculty of Medicine, Osaka, Japan.
Transl Lung Cancer Res ; 12(6): 1167-1184, 2023 Jun 30.
Article en En | MEDLINE | ID: mdl-37425411
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Clinical_trials / Prognostic_studies Idioma: En Revista: Transl Lung Cancer Res Año: 2023 Tipo del documento: Article País de afiliación: Japón
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Clinical_trials / Prognostic_studies Idioma: En Revista: Transl Lung Cancer Res Año: 2023 Tipo del documento: Article País de afiliación: Japón